Abstract
Replicating adenoviruses may prove to be effective anticancer agents if they can be engineered to selectively destroy tumor cells. We have constructed a virus (01/PEME) containing a novel regulatory circuit in which p53-dependent expression of an antagonist of the E2F transcription factor inhibits viral replication in normal cells. In tumor cells, however, the combination of p53 pathway defects and deregulated E2F allows replication of 01/PEME at near wild-type levels. The re-engineered virus also showed significantly enhanced efficacy compared with extensively studied E1b-deleted viruses such as dl1520 in human xenograft tumor models.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Alemany, R., Balague, C. & Curiel, D.T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723–727 (2000).
Kirn, D.H. & McCormick, F. Replicating viruses as selective cancer therapeutics. Mol. Med. Today. 2, 519–527 (1996).
Kirn, D., Martuza, R.L. & Zwiebel, J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat. Med. 7, 781–787 (2001).
Yu, D.C., Sakamoto, G.T. & Henderson, D.R. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 59, 1498–1504 (1999).
Hallenbeck, P.L. et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721–1733 (1999).
Favrot, M., Coll, J.L., Louis, N. & Negoescu, A. Cell death and cancer: replacement of apoptotic genes and inactivation of death suppressor genes in therapy. Gene Ther. 5, 728–739 (1998).
Lin, X., Denmeade, S.R. & Isaacs, J.T. The genetics of programmed (apoptotic) cell death. Cancer Surv. 25, 173–194 (1995).
Bischoff, J.R. et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373–376 (1996).
Rancourt, C. et al. Interleukin-6 modulated conditionally replicative adenovirus as an antitumor/cytotoxic agent for cancer therapy. Clin. Cancer Res. 5, 43–50 (1999).
Fueyo, J. et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2–12 (2000).
Doronin, K. et al. Tumor-specific, replication-competent adenovirus vectors overexpressing the adenovirus death protein. J. Virol. 74, 6147–6155 (2000).
Howe, J. et al. Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Therapy 2, 485–495 (2000).
Heise, C. et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med. 6, 1134–1139 (2000).
Harada, J.N. & Berk, A.J. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. J. Virol. 73, 5333–5344 (1999).
Heise, C. et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639–645 (1997).
Heise, C.C., Williams, A.M., Xue, S., Propst, M. & Kirn, D.H. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy. Cancer Res. 59, 2623–2628 (1999).
Yu, D.C., Chen, Y., Seng, M., Dilley, J. & Henderson, D.R. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200–4203 (1999).
Rogulski, K.R. et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. Cancer Res. 60, 1193–1196 (2000).
Ganly, I. et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798–806 (2000).
Khuri, F.R. et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879–885 (2000).
Kirn, D. et al. A phase II trial of intratumoral injection with an E1B-deleted adenovirus, ONYX-015, in patients with recurrent, refractory head and neck cancer. Proc. Am. Soc. Clin. Oncol. 17, 391a (1998).
Nemunaitis, J. et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J. Clin. Oncol. 19, 289–298 (2001).
Sherr, C.J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689–3695 (2000).
Prives, C. & Hall, P.A. The p53 pathway. J. Pathol. 187, 112–126 (1999).
Tollefson, A.E., Ryerse, J.S., Scaria, A., Hermiston, T.W. & Wold, W.S. The E3–11.6-kDa adenovirus death protein (ADP) is required for efficient cell death: characterization of cells infected with adp mutants. Virology 220, 152–162 (1996).
Sellers, W.R., Rodgers, J.W. & Kaelin, W.G. Jr. A potent transrepression domain in the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. Proc. Natl. Acad. Sci. USA 92, 11544–11548 (1995).
Wills, K.N. et al. Tissue-specific expression of an anti-proliferative hybrid transgene from the human smooth muscle α-actin promoter suppresses smooth muscle cell proliferation and neointima formation. Gene Ther. in press (2001).
Somasundaram, K. & El-Deiry, W.S. Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. Oncogene 14, 1047–1057 (1997).
Lill, N.L., Grossman, S.R., Ginsberg, D., DeCaprio, J. & Livingston, D.M. Binding and modulation of p53 by p300/CBP coactivators. Nature 387, 823–827 (1997).
Howe, J.A., Mymryk, J.S., Egan, C., Branton, P.E. & Bayley, S.T. Retinoblastoma growth suppressor and a 300-kDa protein appear to regulate cellular DNA synthesis. Proc. Natl. Acad. Sci. USA 87, 5883–5887 (1990).
Tollefson, A.E. et al. The adenovirus death protein (E3-11.6K) is required at very late stages of infection for efficient cell lysis and release of adenovirus from infected cells. J. Virol. 70, 2296–2306 (1996).
Parr, M.J. et al. Tumor-selective transgene expression in vivo mediated by an E2F-responsive adenoviral vector. Nat. Med. 3, 1145–1149 (1997).
Nemunaitis, J. et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359–6366 (2000).
Dix, B.R., Edwards, S.J. & Braithwaite, A.W. Does the antitumor adenovirus ONYX-015/dl1520 selectively target cells defective in the p53 pathway? J. Virol. 75, 5443–5447 (2001).
McCormick, F. Interactions between adenovirus proteins and the p53 pathway: the development of ONYX-015. Semin. Cancer Biol. 10, 453–459 (2000).
Ikeda, K. et al. Oncolytic virus therapy of multiple tumors in the brain requires suppression of innate and elicited antiviral responses. Nat. Med. 5, 881–887 (1999).
Funk, W.D., Pak, D.T., Karas, R.H., Wright, W.E. & Shay, J.W. A transcriptionally active DNA-binding site for human p53 protein complexes. Mol. Cell. Biol. 12, 2866–2871 (1992).
Jones, N. & Shenk, T. An adenovirus type 5 early gene function regulates expression of other early viral genes. Proc. Natl. Acad. Sci. USA 76, 3665–3669 (1979).
Thimmappaya, B., Weinberger, C., Schneider, R.J. & Shenk, T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell 31, 543–551 (1982).
Barker, D.D. & Berk, A.J. Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107–121 (1987).
Wills, K.N. et al. Gene therapy for hepatocellular carcinoma: chemosensitivity conferred by adenovirus-mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 2, 191–197 (1995).
Chartier, C. et al. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J. Virol. 70, 4805–4810 (1996).
Huyghe, B.G. et al. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum. Gene Ther. 6, 1403–1416 (1995).
Shabram, P.W. et al. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum. Gene Ther. 8, 453–465 (1997).
Wen, S.F. et al. Retinoblastoma protein monoclonal antibodies with novel characteristics. J. Immunol. Methods 169, 231–240 (1994).
Tollefson, A.E., Scaria, A., Saha, S.K. & Wold, W.S. The 11,600-MW protein encoded by region E3 of adenovirus is expressed early but is greatly amplified at late stages of infection. J. Virol. 66, 3633–3642 (1992).
Musco, M.L. et al. Comparison of flow cytometry and laser scanning cytometry for the intracellular evaluation of adenoviral infectivity and p53 protein expression in gene therapy. Cytometry 33, 290–296 (1998).
Acknowledgements
We thank Drs. Arnie Berk (UCLA) and Stan Bayley (McMaster) for providing dl1520 and dl1101, respectively; Drs. Robert Ralston, Ken Wills, Wendy Hancock, Shu Fen Wen, Dan Maneval, and Stephen Chang for helpful discussions; Mark Horn, Daniel Giroux, and Anastasia Sofianos for virus purification; and Stuart Perry, Todd Machemer, Susan Miller, Margarita Nodelman, Elaine Hurney, Erlinda Quijano, and Henry Kikunaga for technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramachandra, M., Rahman, A., Zou, A. et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 19, 1035–1041 (2001). https://doi.org/10.1038/nbt1101-1035
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/nbt1101-1035
This article is cited by
-
Oncolytic viruses: adenoviruses
Virus Genes (2017)
-
Meganuclease-mediated Virus Self-cleavage Facilitates Tumor-specific Virus Replication
Molecular Therapy (2013)
-
Local sustained delivery of oncolytic adenovirus with injectable alginate gel for cancer virotherapy
Gene Therapy (2013)
-
Adenovirus i-Leader Truncation Bioselected Against Cancer-associated Fibroblasts to Overcome Tumor Stromal Barriers
Molecular Therapy (2012)
-
Clinical development directions in oncolytic viral therapy
Cancer Gene Therapy (2011)